Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 402

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 402
---
 clinical trials and in relation to any future commercialization of its product candidates. NLS’s third -partymanufacturers are responsible for obtaining the raw materials necessary to manufacture NLS’s product candidates, which NLS believes are readily available from more than one source. Additional third -partymanufacturers are and will be used to formulate, fill, label, package and distribute investigational drug products and eventually NLS’s products, if and when NLS’s product candidates receive approval. This approach allows NLS to maintain a more efficient infrastructure while enabling it to focus its expertise on developing and commercializing its product candidates. NLS believes that its current supplier and manufacturers have the capacity to support both clinical supply and commercial -scaleproduction, but NLS does not have any formal agreements at this time for such supply and production, and NLS may also elect to enter into agreements with additional or alternative parties in the future. 200 Commercialization, Sales and Marketing Given its stage of development, NLS does not currently have an established internal sales, marketing or distribution infrastructure. If its product candidates are approved for marketing, NLS intends to commercialize its product candidates either alone or in partnership with others, where appropriate, to maximize the value of its product candidates. NLS expects to build its commercial infrastructure using a focused and efficient approach, initially, establishing market access, sales and marketing capabilities in a targeted manner that is appropriate for the relevant product opportunity. NLS believes that this approach will allow it to effectively reach patients and physicians and to maximize the commercial potential of its product candidates. Organizational Structure NLS is a Swiss stock corporation organized under the laws of Switzerland. NLS’s Swiss enterprise identification number is CHE -447.067.367. NLS’s registered and principal executive offices are located at The Circle6, Postfach, 8058 Zurich, Switzerland. NLS’s general telephone number is (41) 44 512 21 50 and its internet address is www.nlspharma.com. In April 2021, NLS formed a wholly owned subsidiary, NLS Pharmaceutics Inc., a Delaware corporation. In November 2024 NLS also formed Merger Sub, its wholly owned subsidiary, in connection with the Merger. NLS did not have any other subsidiaries as of December 31, 2024, and as of the date of this proxy statement/prospectus. Property, Plant and Equipment NLS’s principal executive office in Postfach, 8058 Zurich, Switzerland, consists of approximately 25